Relation of Circulating Endothelium-derived Microparticle to Carotid Atherosclerosis

March 30, 2015 updated by: Hisashi Kai, Kurume University
The investigators hypothesized that circulating endothelium-derived microparticle (EMP) may be a useful surrogate marker of atherosclerosis and future episode of cerebrovascular events. Peripheral blood is drawn at the time of carotid ultrasound examination. Circulating EMPs are counted using flow-cytometry. The correlation among circulating EMP, ultrasound findings, and atherosclerotic risk factors are determined by multiple stepwise regression analysis. The prevalence of cerebrovascular events is also determined during 3-year follow-up period.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

154

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Fukuoka
      • Kurume, Fukuoka, Japan, 830-0011
        • Kurume University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who undergo carotid ultrasound examination for screening of atheroscrelosis

Description

Inclusion Criteria:

  • Patients who undergo carotid ultrasound examination for screening of atherosclerosis

Exclusion Criteria:

  • Cerebrovascular events within the last 12 months
  • Acute coronary syndrome, coronary and peripheral intervention within the last 6 months
  • Uncontrolled heart failure
  • Other severe systemic diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Carotid atherosclerosis group
Patients who undergo carotid ultrasound examination for carotid atherosclerosis screening

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The number of circulating EMPs
Time Frame: at the time of carotid ultrasound examination
at the time of carotid ultrasound examination

Secondary Outcome Measures

Outcome Measure
Time Frame
The occurrence of cerebrovascular and/or cardiovascular events
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Tsutomu Imaizumi, MD, PhD, Kurume University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2008

Primary Completion (Actual)

November 1, 2010

Study Completion (Actual)

November 1, 2013

Study Registration Dates

First Submitted

November 20, 2008

First Submitted That Met QC Criteria

November 20, 2008

First Posted (Estimate)

November 21, 2008

Study Record Updates

Last Update Posted (Estimate)

March 31, 2015

Last Update Submitted That Met QC Criteria

March 30, 2015

Last Verified

March 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atherosclerosis

3
Subscribe